Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Background and aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage. As this recommendation is largely based on the use of infliximab for rheumatologic dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo, Daniel V., Muniz, Thiago Pimentel, Yang, Anjie, Keshavarzi, Sareh, Sorotsky, Hadas, Butler, Marcus O., Saibil, Samuel, Spreafico, Anna, Hogg, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293058/
https://www.ncbi.nlm.nih.gov/pubmed/34208089
http://dx.doi.org/10.3390/curroncol28030201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293058/
https://www.ncbi.nlm.nih.gov/pubmed/34208089
http://dx.doi.org/10.3390/curroncol28030201

Ejemplares similares